Drug Trial Radar · NCT07222761
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
915
Planned (sponsor's estimate)
Start
Jan 2, 2026
Primary completion
May 21, 2029
Study completion Aug 23, 2034
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Oct 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called carfilzomib, compared to several standard treatments for progressive Multiple Myeloma (MM) after at least 1 but no more than 3 prior therapies. The aim of this study is to see if the safety and efficacy of linvoseltamab alone or in combination with carfilzomib can deliver better outcomes (deeper and longer responses that help extend life) than standard treatment options. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Conditions
- Relapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions
LinvoseltamabDrug
Administered per the protocol
CarfilzomibDrug
Administered per the protocol
DaratumumabDrug
Administered per the protocol
DexamethasoneDrug
Administered per the protocol
PomalidomideDrug
Administered per the protocol
BortezomibDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 5 years
- Severity of TEAEsTime frame: Up to 5 years
- Occurrence of Adverse Events of Special Interest (AESI)Time frame: Up to 5 years
- Severity of AESIsTime frame: Up to 5 years
- Occurrence of Serious Adverse Events (SAEs)Time frame: Up to 5 years
- Severity of SAEsTime frame: Up to 5 years
- Minimal Residual Disease (MRD)-negative Complete Response (CR)Time frame: At 12 months
- Progression-Free Survival (PFS) per IMWG response criteria as determined by BIRCTime frame: Up to 5 years
Locations
60 sites in 9 countries. Site status is shown where the registry gives one.
Emory Winship Cancer Institute
Atlanta, Georgia · Recruiting
Trinity Health St. Joseph Ann Arbor Hospital
Ann Arbor, Michigan · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Stony Brook University Hospital
Stony Brook, New York · Recruiting
OhioHealth
Columbus, Ohio · Recruiting
Baylor University Medical Center
Dallas, Texas · Recruiting
University of Texas Health Science Center, Houston
Houston, Texas · Recruiting
Royal Adelaide Hospital
Adelaide, Australia · Recruiting
Pindara Private Hospital
Benowa, Queensland, Australia · Recruiting
Mater Misericordiae Ltd
Brisbane, Queensland, Australia · Recruiting
Gold Coast Hospital and Health Service
Southport, Queensland, Australia · Recruiting
Epworth Freemasons
East Melbourne, Victoria, Australia · Recruiting
Austin Hospital
Heidelberg, Victoria, Australia · Recruiting
Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Royal Perth Hospital
Perth, Western Australia, Australia · Recruiting
AC Camargo Cancer Center
São Paulo, Brazil · Recruiting
Clinica Medica Sao Germano
São Paulo, Brazil · Recruiting
Cetus Oncologia
Belo Horizonte, Minas Gerais, Brazil · Recruiting
Hospital Erasto Gaertner
Curitiba, Paraná, Brazil · Recruiting
Oncomed Clinica Oncologica
Niterói, Rio de Janeiro, Brazil · Recruiting
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Centro Gaucho Integrado, Hospital Mae de Deus
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Centro de Hematologia e Oncologia
Joinville, Santa Catarina, Brazil · Recruiting
ANIMI
Lages, Santa Catarina, Brazil · Recruiting
Unidade de Pesquisa Clinica (UPC); Hospital das Clinicas de Ribeirao Preto da Universidade de Sao Paulo
Ribeirão Preto, São Paulo, Brazil · Recruiting
Hospital Clinico Universidad de Los Andes
Santiago, Las Condes, Chile · Recruiting
Clinica Alemana de Santiago
Santiago, Santiago Metropolitan, Chile · Recruiting
Clinica UC San Carlos de Apoquindo
Santiago, Santiago Metropolitan, Chile · Recruiting
OncoPrecision
Santiago, Santiago Metropolitan, Chile · Recruiting
Centro de Investigaciones Clinicas Vina del Mar
Viña del Mar, Valparaiso, Chile · Recruiting
Japanese Red Cross Fukuoka Hospital
Fukuoka, Japan · Recruiting
Gunma University Hospital
Maebashi, Gunma, Japan · Recruiting
Tokushima Prefectural Central Hospital
Tokushima, Tokushima, Japan · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Severance Hospital; Division of Hematology
Seoul, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Seoul St. Mary's Hospital, The Catholic University of Korea
Seoul, South Korea · Recruiting
Ulsan University Hospital
Ulsan, South Korea · Recruiting
Chonnam National University Hwasun Hospital
Hwasun, Jeollanam-do, South Korea · Recruiting
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.